Published in JCI Insight on December 08, 2016
Targeting cellular senescence prevents age-related bone loss in mice. Nat Med (2017) 1.39
Recent Advances in Understanding and Managing Cardiomyopathy. F1000Res (2017) 0.75
Mutations in PTPN11, encoding the protein tyrosine phosphatase SHP-2, cause Noonan syndrome. Nat Genet (2001) 6.96
Pathological hypertrophy and cardiac interstitium. Fibrosis and renin-angiotensin-aldosterone system. Circulation (1991) 4.65
Mouse model of Noonan syndrome reveals cell type- and gene dosage-dependent effects of Ptpn11 mutation. Nat Med (2004) 3.55
Crystal structure of the tyrosine phosphatase SHP-2. Cell (1998) 3.48
Atrial natriuretic peptide elevation in congestive heart failure in the human. Science (1986) 3.37
Noonan syndrome and related disorders: genetics and pathogenesis. Annu Rev Genomics Hum Genet (2005) 3.02
PTPN11 mutations in Noonan syndrome: molecular spectrum, genotype-phenotype correlation, and phenotypic heterogeneity. Am J Hum Genet (2002) 2.81
Genetic causes of human heart failure. J Clin Invest (2005) 2.79
Diverse biochemical properties of Shp2 mutants. Implications for disease phenotypes. J Biol Chem (2005) 2.60
Noonan syndrome: clinical features, diagnosis, and management guidelines. Pediatrics (2010) 2.56
Prognostic, therapeutic, and mechanistic implications of a mouse model of leukemia evoked by Shp2 (PTPN11) mutations. Cancer Cell (2005) 2.51
Noonan syndrome and related disorders: dysregulated RAS-mitogen activated protein kinase signal transduction. Hum Mol Genet (2006) 2.31
Activation of the SH2-containing phosphotyrosine phosphatase SH-PTP2 by its binding site, phosphotyrosine 1009, on the human platelet-derived growth factor receptor. J Biol Chem (1993) 2.13
Protein-tyrosine-phosphatase SHPTP2 couples platelet-derived growth factor receptor beta to Ras. Proc Natl Acad Sci U S A (1994) 1.92
Rapamycin reverses hypertrophic cardiomyopathy in a mouse model of LEOPARD syndrome-associated PTPN11 mutation. J Clin Invest (2011) 1.84
Noonan syndrome and clinically related disorders. Best Pract Res Clin Endocrinol Metab (2011) 1.82
Mechanism and treatment for learning and memory deficits in mouse models of Noonan syndrome. Nat Neurosci (2014) 1.63
Cardiac response to pressure overload in 129S1/SvImJ and C57BL/6J mice: temporal- and background-dependent development of concentric left ventricular hypertrophy. Am J Physiol Heart Circ Physiol (2006) 1.52
Mediating ERK 1/2 signaling rescues congenital heart defects in a mouse model of Noonan syndrome. J Clin Invest (2007) 1.48
MEK-ERK pathway modulation ameliorates disease phenotypes in a mouse model of Noonan syndrome associated with the Raf1(L613V) mutation. J Clin Invest (2011) 1.39
The natural history of Noonan syndrome: a long-term follow-up study. Arch Dis Child (2006) 1.29
Noonan syndrome cardiac defects are caused by PTPN11 acting in endocardium to enhance endocardial-mesenchymal transformation. Proc Natl Acad Sci U S A (2009) 1.25
Phosphatase-dependent and -independent functions of Shp2 in neural crest cells underlie LEOPARD syndrome pathogenesis. Dev Cell (2010) 1.22
Characterization of blood pressure and morphological traits in cardiovascular-related organs in 13 different inbred mouse strains. J Appl Physiol (1985) (2004) 1.21
Activation of multiple signaling pathways causes developmental defects in mice with a Noonan syndrome–associated Sos1 mutation. J Clin Invest (2010) 1.21
Distinct molecular phenotypes in murine cardiac muscle development, growth, and hypertrophy. J Mol Cell Cardiol (1998) 1.21
Structural determinants of SHP-2 function and specificity in Xenopus mesoderm induction. Mol Cell Biol (1998) 1.17
RASopathies: Clinical Diagnosis in the First Year of Life. Mol Syndromol (2011) 1.07
Gain-of-function/Noonan syndrome SHP-2/Ptpn11 mutants enhance calcium oscillations and impair NFAT signaling. Proc Natl Acad Sci U S A (2006) 1.01
Noonan syndrome is associated with enhanced pERK activity, the repression of which can prevent craniofacial malformations. Proc Natl Acad Sci U S A (2009) 1.01
Adults with genetic syndromes and cardiovascular abnormalities: clinical history and management. Genet Med (2008) 0.98
Dasatinib in chronic myeloid leukemia: a review. Ther Clin Risk Manag (2009) 0.98
Purification and cloning of PZR, a binding protein and putative physiological substrate of tyrosine phosphatase SHP-2. J Biol Chem (1998) 0.98
Hypertrophic cardiomyopathy in Noonan syndrome. Acta Paediatr Jpn (1996) 0.95
Noonan syndrome-associated SHP-2/Ptpn11 mutants enhance SIRPalpha and PZR tyrosyl phosphorylation and promote adhesion-mediated ERK activation. J Biol Chem (2008) 0.93
Amplification of MPZL1/PZR promotes tumor cell migration through Src-mediated phosphorylation of cortactin in hepatocellular carcinoma. Cell Res (2013) 0.92
Cell surface glycoprotein PZR is a major mediator of concanavalin A-induced cell signaling. J Biol Chem (2001) 0.91
Primary culture of adult rat heart myocytes. J Vis Exp (2009) 0.89
Dissecting the interaction of SHP-2 with PZR, an immunoglobulin family protein containing immunoreceptor tyrosine-based inhibitory motifs. J Biol Chem (2000) 0.87
Novel mesenchymal and haematopoietic cell isoforms of the SHP-2 docking receptor, PZR: identification, molecular cloning and effects on cell migration. Biochem J (2003) 0.87
SHP2 sails from physiology to pathology. Eur J Med Genet (2015) 0.86
Structural insights into Noonan/LEOPARD syndrome-related mutants of protein-tyrosine phosphatase SHP2 (PTPN11). BMC Struct Biol (2014) 0.86
The murine ortholog of the SHP-2 binding molecule, PZR accelerates cell migration on fibronectin and is expressed in early embryo formation. J Cell Biochem (2007) 0.85
Dasatinib Attenuates Pressure Overload Induced Cardiac Fibrosis in a Murine Transverse Aortic Constriction Model. PLoS One (2015) 0.84
Molecular basis of gain-of-function LEOPARD syndrome-associated SHP2 mutations. Biochemistry (2014) 0.84
Noonan's cardiomyopathy: a non-hypertrophic variant. Br Heart J (1994) 0.83
Dilated cardiomyopathy in Noonan's syndrome. Int J Cardiol (1996) 0.82
A PTPN11 allele encoding a catalytically impaired SHP2 protein in a patient with a Noonan syndrome phenotype. Am J Med Genet A (2014) 0.82
Phosphorylation and localization of protein-zero related (PZR) in cultured endothelial cells. Endothelium (2008) 0.81
PZR coordinates Shp2 Noonan and LEOPARD syndrome signaling in zebrafish and mice. Mol Cell Biol (2014) 0.81
K-RasV14I recapitulates Noonan syndrome in mice. Proc Natl Acad Sci U S A (2014) 0.81
Cardiac findings in Noonan syndrome on long-term follow-up. Congenit Heart Dis (2013) 0.80
Elevated Ca2+ transients and increased myofibrillar power generation cause cardiac hypercontractility in a model of Noonan syndrome with multiple lentigines. Am J Physiol Heart Circ Physiol (2015) 0.79
Hypertrophic cardiomyopathy progressing to a dilated cardiomyopathy-like feature in Noonan's syndrome. Am Heart J (1992) 0.79
Rapidly progressive hypertrophic cardiomyopathy in an infant with Noonan syndrome with multiple lentigines: palliative treatment with a rapamycin analog. Am J Med Genet A (2015) 0.78
The third international meeting on genetic disorders in the RAS/MAPK pathway: towards a therapeutic approach. Am J Med Genet A (2015) 0.76
Dilated cardiomyopathy in Noonan's syndrome: a first autopsy case. Hum Pathol (2000) 0.76
Restrictive and hypertrophic cardiomyopathies in Noonan syndrome: the overlap syndromes. Heart (1996) 0.76